Novel FASN inhibitors developed by Sagimet Biosciences show anti-cancer activity in lung, prostate, ovarian, and colon cancer models in vitro and in vivo (8–10), and are currently being tested in phase I/II clinical trials (11–13). Here, FASN is linked to cancer.